Skip to main content
CNSP logo
CNSP
(NASDAQ)
CNS Pharmaceuticals, Inc.
$4.78-- (--)
Loading... - Market loading

CNS Pharmaceuticals (CNSP) Cash Flow Statement

Operating, investing, and financing activities with annual and quarterly data.

CNS Pharmaceuticals Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for CNS Pharmaceuticals, Inc. (CNSP) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2024FY 2023FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period EndingDec 2025Mar 2025Dec 2024Mar 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income-15.85-14.86-14.86-18.85-18.85-15.27-14.50-9.46-3.88-7.39-0.22
Depreciation & Amortization0.000.000.000.000.000.010.010.010.000.000.00
Stock Based Compensation0.190.840.841.011.011.201.721.290.480.110.12
Change in Working Capital1.85-3.69-3.693.703.703.16-0.780.83-0.430.080.05
Change in Accounts Payable0.00-3.63-3.631.321.321.701.040.660.150.070.06
Change in Other Working Capital1.85-0.060.602.382.380.86-1.520.18-0.580.01-0.01
Other Operating Activities0.000.600.600.000.000.340.000.000.276.48-0.06
Net Cash from Operating Activities-13.81-17.11-17.11-14.14-14.14-10.56-13.54-7.32-3.55-0.72-0.11
Investing Activities
Capital Expenditures-0.020.000.000.000.000.00-0.01-0.02-0.020.000.00
Net Cash from Investing Activities-0.020.000.000.000.000.00-0.01-0.02-0.020.000.00
Financing Activities
Debt Repayment-0.30-0.30-0.30-0.44-0.44-0.43-0.48-0.04-0.040.300.12
Common Stock Issued14.0523.3823.382.322.3216.044.9914.2210.290.390.10
Common Stock Repurchased0.000.000.000.000.000.000.000.000.000.000.00
Other Financing Activities0.82-0.05-0.072.76-0.200.000.33-0.050.000.470.00
Net Cash from Financing Activities14.5723.0323.034.644.6415.614.5114.1310.261.160.22
Summary
Net Change in Cash0.745.915.91-9.51-9.515.05-9.036.806.690.440.11
Cash at Beginning of Period6.460.550.5510.0610.065.0014.047.240.560.110.00
Cash at End of Period7.206.466.460.550.5510.065.0014.047.240.560.11
Free Cash Flow-13.83-17.12-17.12-14.14-14.14-10.56-13.54-7.34-3.57-0.72-0.11
Supplemental Disclosures
Interest Paid0.000.000.010.000.010.010.010.000.000.000.00

Frequently Asked Questions About CNS Pharmaceuticals Cash Flow

What is a cash flow statement?

A cash flow statement tracks the actual cash moving in and out of a company during a period. It's divided into three sections: operating activities (core business), investing activities (assets and investments), and financing activities (debt and equity). Unlike the income statement, it shows real cash rather than accounting profits.

What is operating cash flow?

Operating cash flow is the cash generated from a company's core business operations. It adjusts net income for non-cash items like depreciation and changes in working capital. Strong operating cash flow indicates the business can fund operations without external financing.

What is free cash flow (FCF)?

Free cash flow is operating cash flow minus capital expenditures. It represents the cash available for dividends, share buybacks, debt repayment, or reinvestment. FCF is considered one of the most important metrics for evaluating a company's financial health.

What are capital expenditures?

Capital expenditures (CapEx) are funds spent on acquiring or maintaining physical assets like property, equipment, and technology. CapEx appears in the investing activities section and is subtracted from operating cash flow to calculate free cash flow.

How is CNSP's cash generation trending?

Review CNS Pharmaceuticals's operating cash flow and free cash flow figures in the quarterly and annual data above. Consistent growth in operating cash flow relative to net income indicates high-quality earnings.

These financial metrics are calculated using cash flow data. Learn how each metric works and screen stocks by them.